National Cancer Institute Grant: Exploring Erythropoiesis Stimulating Agents and Tumor Progression

Opportunity ID: 43317

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-09-023
Funding Opportunity Title: Erythropoiesis Stimulating Agents and Tumor Progression (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.393 — Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Nov 06, 2008
Last Updated Date:
Original Closing Date for Applications: Jan 07, 2012
Current Closing Date for Applications: Jan 07, 2012
Archive Date: Feb 07, 2012
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: County governments
City or township governments
Special district governments
Independent school districts
Small businesses
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Private institutions of higher education
State governments
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: -Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression.
-Mechanism of Support. This FOA uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-024 that encourages applications under the NIH Exploratory/Developmental (R21) Grant mechanism.
-Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-09-023.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
ADOBE-FORMS-A Adobe-Forms-A PKG00009529 Jan 05, 2009 Feb 20, 2010 View
ADOBE-FORMS-B Use for submissions intended for due dates of January 25, 2010 and beyond PKG00015214 Dec 21, 2009 Oct 14, 2010 View
ADOBE-FORMS-B1 Supersedes ADOBE-FORMS-B PKG00021884 Oct 14, 2010 Jan 07, 2012 View

Package 1

Mandatory forms

43317 RR_SF424-1.1.pdf

43317 RR_KeyPersonExpanded-1.1.pdf

43317 RR_OtherProjectInfo-1.1.pdf

43317 RR_PerformanceSite-1.1.pdf

43317 PHS398_CoverPageSupplement-1.1.pdf

43317 PHS398_ResearchPlan-1.1.pdf

43317 PHS398_Checklist-1.1.pdf

Optional forms

43317 PHS398_CoverLetter-1.1.pdf

43317 PHS398_ModularBudget-1.1.pdf

43317 RR_Budget-1.1.pdf

43317 RR_SubawardBudget-1.2.pdf

Package 2

Mandatory forms

43317 RR_SF424_1_2-1.2.pdf

43317 PerformanceSite_1_3-1.3.pdf

43317 RR_OtherProjectInfo_1_2-1.2.pdf

43317 RR_KeyPersonExpanded_1_2-1.2.pdf

43317 PHS398_CoverPageSupplement_1_4-1.4.pdf

43317 PHS398_ResearchPlan_1_3-1.3.pdf

43317 PHS398_Checklist_1_3-1.3.pdf

Optional forms

43317 PHS_CoverLetter_1_2-1.2.pdf

43317 PHS398_ModularBudget-1.1.pdf

43317 RR_Budget-1.1.pdf

43317 RR_SubawardBudget-1.2.pdf

Package 3

Mandatory forms

43317 RR_SF424_1_2-1.2.pdf

43317 RR_OtherProjectInfo_1_3-1.3.pdf

43317 RR_KeyPersonExpanded_1_2-1.2.pdf

43317 PerformanceSite_1_4-1.4.pdf

43317 PHS398_ResearchPlan_1_3-1.3.pdf

43317 PHS398_CoverPageSupplement_1_4-1.4.pdf

43317 PHS398_Checklist_1_3-1.3.pdf

Optional forms

43317 RR_Budget-1.1.pdf

43317 RR_SubawardBudget-1.2.pdf

43317 PHS_CoverLetter_1_2-1.2.pdf

43317 PHS398_ModularBudget-1.1.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *